Middle East & Africa Pharmaceutical Drug Delivery Market

The Middle East & Africa pharmaceutical drug delivery market is projected to reach USD 48.22 billion by 2031 from USD 38.20 billion in 2026, at a CAGR of 4.8%.

The Middle East & Africa pharmaceutical drug delivery market has been growing steadily, reflected in the rapid launch of biologics, biosimilars, and next-generation therapies across major healthcare systems in Saudi Arabia, the UAE, South Africa, Egypt, and several developing African economies. As these therapies are increasingly adopted, there has been an upsurge in the demand for delivery systems that satisfy three main characteristics: reliability, improved drug stability, and enhanced therapeutic precision. Furthermore, the increasing incidences of chronic and lifestyle-related diseases, mainly cancer, diabetes, respiratory diseases, and autoimmune disorders, are pushing forward the transformation toward the use of more advanced delivery devices such as long-acting injectables, self-administration devices, inhalation systems, transdermal technologies, and subcutaneous platforms.

To know about the assumptions considered for the study download the pdf brochure

At the same time, advancements in prefilled syringe technology, smart injectors, wearable drug-delivery devices, and advanced inhalers are continually creating new opportunities for drug manufacturers across the region. Overcrowding in public hospitals, a preference for home-based care, and the emergence of new outpatient treatment models are other major factors driving the adoption of modern drug delivery solutions that facilitate drug administration, ensure patient safety, and enable continuous therapy management. Additionally, increasing investments in research and development, the expansion of biologics manufacturing capabilities, and evolving regulatory frameworks—driven by agencies such as the Saudi FDA, UAE MOHAP, and SAHPRA are shaping a more supportive environment for drug–device combination products throughout MEA.

Currently, some major players active in the Middle East & Africa pharmaceutical drug delivery market are Sanofi (France), Pfizer Inc. (US), Novartis AG (Switzerland), AstraZeneca (UK), GSK plc (UK), Hikma Pharmaceuticals plc (UK), Bayer AG (Germany), F. Hoffmann-La Roche (Switzerland), Novo Nordisk A/S (Denmark), Johnson & Johnson services, Inc. (US), and BD (US).

To expand their regional footprint and increase market share in the Middle East & Africa pharmaceutical drug delivery market, companies are adopting several strategic initiatives, including partnerships, licensing agreements, product portfolio expansion, regulatory approvals for advanced biologics, and strengthening distribution networks across emerging markets. These strategies enable manufacturers to expand access to innovative drug-delivery solutions and address the growing demand for treatments for chronic and infectious diseases across the region.

In October 2025, Hikma Pharmaceuticals expanded its partnership with Celltrion Inc. through exclusive licensing agreements to commercialize six additional biosimilars across the Middle East and North Africa (MENA). These biosimilars address key therapeutic areas, including oncology, autoimmune diseases, allergic disorders, and ophthalmology. The agreement is likely to strengthen Hikma’s position in the hospital and specialty-care sectors and enhance patient access to high-quality biologic treatments across the region.

In March 2025, Johnson & Johnson Services, Inc. (US) was granted US FDA approval for TREMFYA (guselkumab) for the treatment of moderately to severely active Crohn's disease in adults. TREMFYA is the first and only interleukin-23 (IL-23) inhibitor to offer both subcutaneous (SC) and intravenous (IV) induction options. This regulatory achievement opens the possibility for doctors and patients to have more options for starting and continuing treatment with either IV or SC delivery, paving the way for biologic drug delivery innovations in immune-mediated inflammatory disorders.

In December 2024, BD expanded its injectable drug delivery portfolio by launching the BD EffiFlow Advanced Prefillable Syringe Platform. This new platform is designed to enhance compatibility with biologics, reduce extrusion force, and improve safety during the administration of high-viscosity drugs. This expansion reinforces BD’s leadership in prefillable syringes and addresses the growing demand for self-injection solutions in the US biologics and specialty drug markets.

Sanofi (France)

Sanofi manufactures and sells healthcare products. It operates through two business segments: Biopharma and Consumer Healthcare. The Biopharma segment comprises commercial operations and research, development, and production activities for the specialty care, general medicines, and vaccines franchises. The company offers various products for diabetes, rare diseases, multiple sclerosis, oncology, thrombosis, cardiovascular disease prevention, nephrology, and biosurgery. Through the Vaccines segment, the company offers vaccines in five major areas: pediatric, influenza, adult & adolescent boosters, meningitis, and travel & endemic. It offers pharmaceutical drug delivery products across both segments. The company operates in the US, Europe, the Middle East, Africa, Asia, and Russia. Some of its notable subsidiaries include Aventis, Inc. (US), Aventis Pharma S.A. (France), Hoechst GmbH (Germany), Sanofi Pasteur-Aventis Deutschland GmbH (Germany), Sanofi Pasteur (France), and Sanofi Winthrop Industrie (France).

Pfizer Inc. (US)

Pfizer Inc. holds a prominent position in the US pharmaceutical drug delivery market. The company benefits from advanced therapeutics, mRNA technology, and drug-device combinations. Pfizer’s innovative work in nucleic acid-based delivery, including lipid nanoparticle (LNP) systems used in mRNA vaccines and new gene therapy candidates, has made it a leader in next-generation drug delivery. Moreover, Pfizer manufactures a wide range of medicines for oral, injectable, inhalation, and sustained-release purposes, which are readily available, ensuring therapeutic precision and patient adherence through treatments for immunology, oncology, cardiovascular, and infectious diseases. The company’s strong collaboration partners, extensive formulation expertise, and large US manufacturing capacity all facilitate rapid scaling and dependable supply of advanced delivery systems. Alongside this, digital health integration, self-administration technology, and improved delivery methods for complex biologics are other factors that are continually developing and helping maintain Pfizer’s status as one of the leading and progressive companies in the US pharmaceutical drug delivery market.

Novartis AG (Switzerland)

Novartis AG is a leading player in the pharmaceutical drug delivery market due to its significant presence across geographies. It has a robust portfolio of pharmaceutical drug delivery products. The company has strong brand recognition and offers a robust product portfolio across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology therapeutic areas. The company has put maximum effort into its selected growth fields and prioritizes businesses for resource allocation. Novartis has also strengthened its operations through partnerships, collaborations, and agreements.

AstraZeneca (UK)

AstraZeneca plc is an innovative pharmaceutical company focused on oncology, cardiovascular, renal, metabolism, and respiratory diseases. The company is involved in discovering, developing, and manufacturing an extensive portfolio of prescription medicines used in specialty and primary care. The company operates in a single business segment. However, therapy areas are classified into oncology, rare diseases, and biopharmaceuticals. Geographically, the company operates in more than 160 countries across North America, Europe, the Middle East, Africa, and Asia Pacific. Some of its notable subsidiaries are MedImmune (US), Pearl Therapeutics (US), Amylin Pharmaceuticals (US), and AstraZeneca Pharmaceuticals LP (US).

GSK plc (UK)

GSK plc is a global healthcare company that manufactures healthcare products. The company operates through two business segments: Commercial Operations and Total R&D. The Commercial Operations segment is further segmented into Vaccines, Specialty Medicines, and General Medicines. The company offers pharmaceutical drug delivery products for the treatment of chronic and acute diseases through its Commercial Operations segment. GSK has a strong presence in more than 150 countries, with manufacturing units in 13 countries across the US, Europe, Latin America, the Middle East, Africa, and Asia Pacific. Some of its subsidiaries include GlaxoSmithKline Mexico S.A. de C.V. (Mexico) and Aspen Pharmacare Holdings Limited (South Africa).

Market Ranking

The leading companies in the Middle East & Africa pharmaceutical drug delivery market are Sanofi (France), Pfizer Inc. (US), Novartis AG (Switzerland), AstraZeneca (UK), and GSK plc (UK).

The Middle East & Africa pharmaceutical drug delivery market is consolidated, with the top 5 players accounting for more than 50% of the market share. Sanofi is reinforcing its regional leadership by offering a comprehensive portfolio of injectable biologics, insulin delivery systems, and vaccines that support chronic disease management and immunization programs in MEA. Pfizer enjoys robust market momentum, fueled by its growing presence in injectable therapies, sterile formulations, and self-administration platforms that facilitate access to oncology and specialty treatments across the region. Novartis is increasing its presence in MEA by expanding the use of autoinjectors, long-acting injectable treatments, and patient-friendly delivery systems compatible with biologics and complex therapies. AstraZeneca accelerates growth in the MEA drug delivery market by advancing respiratory inhaler platforms, injectable biologics, and targeted therapies across major therapeutic areas. GSK still has an impactful presence through its leadership in pulmonary drug delivery systems, vaccines, and self-administrable treatments that not only improve adherence but also expand access in the Middle Eastern and African markets.

The accelerated growth of long-acting injectables, higher self-injection systems, inhalation devices, controlled-release formulations, and next-generation delivery platforms is contributing to the commercial momentum of these leading companies in the Middle East & Africa pharmaceutical drug delivery market.

Related Reports:

Middle East & Africa Pharmaceutical Drug Delivery Market by Route of Administration (Injectable [Syringe, Auto injector], Oral [Tablet, Capsule, Syrup], Topical, Nasal, Ocular, Rectal), Application (Cancer, Diabetes, CVD, Ophthalmic) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com